Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 9;116(10):1787-94.
doi: 10.1182/blood-2009-10-250910. Epub 2010 Jun 1.

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis

Affiliations

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis

Thomas A White et al. Blood. .

Abstract

The antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPI(Flox)) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPI(Tie2)) and myelomonocytic (TFPI(LysM)) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPI(Tie2) (71% ± 0.9%, P < .001) and TFPI(LysM) (19% ± 0.6%, P < .001) compared with TFPI(Flox) littermate controls. Tail and cuticle bleeding were unaffected. However, TFPI(Tie2) mice but not TFPI(LysM) mice had increased ferric chloride-induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
TFPI targeting vector with 5′ DNA probe Southern blot screening. (A) Schematic representation of the introduction of the targeting vector and subsequent removal of the PGK-NEO cassette using flippase-mediated flippase recombination target site. (B) 129Sv/J embryonic stem cells were screened for successful targeting of TFPI exon 4 using Southern blot analysis that used a 5′ DNA probe differentiating wild-type and floxed alleles. (C) Germline transmission of the targeting vector was also assessed using Southern blot screening.
Figure 2
Figure 2
Transcriptional efficiency of Cre-mediated deletion. (A) Tie2-directed deletion of TFPI-K1 had high-efficiency deletion of TFPI-K1 in vascular endothelial cells, bone marrow cells, and circulating blood cells. (B) LysM-directed deletion resulted in partial deletion of TFPI-K1 in cells from whole blood and bone marrow.
Figure 3
Figure 3
Plasma TFPI activities. (A) TFPI activities were measured in plasma from mice that contain a floxed TFPI-K1 domain and either do not express Cre recombinase (TFPIFlox) or express the Cre recombinase via the endothelial specific promoter for Tie2 (TFPITie2) or the myelomonocytic specific promoter for LysM (TFPILysM). Animals that express Cre recombinase have a TFPI K1 domain deletion, which is the domain necessary for TFPI inhibition of the TF coagulation pathway. TFPITie2 mice have significantly reduced circulating TFPI activity levels compared with TFPIFlox (*P < .001) and TFPILysM mice (†P < .001). The TFPILysM mice have significantly lower circulating TFPI activities than TFPIFlox littermate controls (*P < .001; panel A). (B) Heparin infusion fails to increase plasma TFPI activity in TFPITie2 mice.
Figure 4
Figure 4
Murine model of thrombosis in TFPILysM mice. Thrombosis was examined using a FeCl3 arterial injury model in TFPIFlox and TFPILysM mice. A flow probe was used to determine when the carotid arteries of TFPIFlox and TFPILysM mice became occluded. (A) No significant differences were observed in times to occlusion between TFPIFlox and TFPILysM mice. (B) Percent patency was plotted against time using a Kaplan-Meier survival plot and χ2 analysis revealed no significant differences of plots for TFPIFlox and TFPILysM mice (P = .25).
Figure 5
Figure 5
Murine model of thrombosis in TFPITie2 mice. Thrombosis was examined using a FeCl3 arterial injury model in TFPIFlox and TFPITie2 mice. A flow probe was used to determine when the carotid arteries of TFPIFlox and TFPITie2 mice became occluded. (A) Times to occlusion were significantly reduced in TFPITie2 mice compared with TFPIFlox mice (*P < .001). (B) Percentage of patency was plotted against time using a Kaplan-Meier survival plot, and χ2 analysis revealed a significant difference between plots for TFPIFlox and TFPILysM mice (P = .007).

Comment in

  • Balancing clotting.
    Mackman N. Mackman N. Blood. 2010 Sep 9;116(10):1634-5. doi: 10.1182/blood-2010-06-289918. Blood. 2010. PMID: 20829379 No abstract available.

Similar articles

Cited by

References

    1. Rosenberg RD, Aird WC. Vascular-bed–specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340(20):1555–1564. - PubMed
    1. Broze GJ, Jr, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci U S A. 1987;84(7):1886–1890. - PMC - PubMed
    1. Novotny WF, Girard TJ, Miletich JP, Broze GJ., Jr Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264(31):18832–18837. - PubMed
    1. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci U S A. 1990;87(22):8869–8873. - PMC - PubMed
    1. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood. 1991;78(2):394–400. - PubMed

Publication types

MeSH terms

Substances